A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome

Trial Profile

A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 12 Sep 2016 Planned initiation date changed from 1 Apr 2016 to 1 Dec 2016.
    • 12 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top